Efficacy and safety of sacubitril/allisartan for the treatment of primary hypertension: a phase 2 randomized, double-blind study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of sacubitril/allisartan for the treatment of primary hypertension: a phase 2 randomized, double-blind study

Published:2023-05-31 Issue:8 Volume:46 Page:2024-2032
ISSN:0916-9636
Container-title:Hypertension Research
language:en
Short-container-title:Hypertens Res

Author:

Zhang Jin,Zhang Wei,Yan Jie,Ge Qian,Lu Xiao-Hong,Chen Shao-Xing,Xu Wen-Jie,Li Ying,Li Jin-Feng,He Shi-Ying,Wang Ji-Guang

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Physiology,Internal Medicine

Link

https://www.nature.com/articles/s41440-023-01326-7.pdf

Reference24 articles.

1. Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18:785–802.

2. Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang ZG, et al. China Hypertension Survey Investigators. Status of hypertension in China: Results from the China Hypertension Survey, 2012-2015. Circulation. 2018;137:2344–56.

3. Chen X, Xu SK, Guo QH, Hu Z, Wang HY, Yu J, et al. Barriers to blood pressure control in China in a large opportunistic screening. J Clin Hypertens. 2020;22:835–41.

4. Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind placebo-controlled, active comparator study. Lancet. 2010;375:1255–66.

5. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Sacubitril/Allisartan for the Treatment of Primary Hypertension;JACC: Asia;2024-09

2. Protective effect of novel angiotensin receptor neprilysin inhibitor S086 on target organ injury in spontaneously hypertensive rats;Biomedicine & Pharmacotherapy;2024-01

3. Polypill Therapy for Cardiovascular Disease Prevention and Combination Medication Therapy for Hypertension Management;Journal of Clinical Medicine;2023-11-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3